Table 1. Baseline Characteristics of Patients.
| Patients with Follow-Up (n = 37) | |
|---|---|
| Age, years | 41.5 ± 17.5 |
| Female | 15 (40.5) |
| BMI, kg/m2 | 22.5 ± 2.8 |
| Past history | |
| Hypertension | 3 (8.1) |
| Hypercholesterolemia | 0 (0) |
| Diabetes | 2 (5.4) |
| Smoking | 7 (18.9) |
| Duration between symptom onset and CMR examination, days | 11.6 ± 8.5 |
| Clinical presentation | |
| Respiratory symptoms | 16 (43.2) |
| Chest pain | 22 (59.5) |
| Palpitation | 2 (5.4) |
| Dyspnea | 22 (59.5) |
| Presyncope or syncope | 12 (32.4) |
| Fever | 10 (27.0) |
| ECG alteration | 31 (83.8) |
| ST elevation | 15 (40.5) |
| ST depression | 9 (24.3) |
| Negative T | 7 (18.9) |
| Pathologic Q | 4 (10.8) |
| AV block | 4 (10.8) |
| LBBB or RBBB | 4 (10.8) |
| Ventricular tarchycardia | 1 (2.7) |
| Initial NYHA functional class | |
| I/II | 15 (40.5) |
| III/IV | 22 (59.5) |
| Initial blood testing | |
| Troponin I, ng/mL | 9.5 ± 13.0 |
| BNP, pg/mL | 1168.7 ± 1229.3 |
| CK-MB, ug/L | 39.0 ± 36.5 |
| Patients who underwent endomyocardial biopsy | 7 (18.9) |
| Beta-blocker medication | 20 (54.1) |
| MACE | 11 (29.7) |
Data are provided as n (%) or mean ± SD. AV = atrioventricular, BMI = body mass index, BNP = brain natriuretic peptide, CK-MB = creatine kinase MB, CMR = cardiovascular magnetic resonance, ECG = electrocardiography, LBBB = left bundle branch block, MACE = major adverse cardiovascular events, NYHA = New York Heart Association, RBBB = right bundle branch block